Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized phase 2 trial of apixaban versus standard anticoagulation for pediatric venous thromboembolism
MOH_2018-03-06_002206Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of apixaban in venous thromboembolism (VTE) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Primary safety endpoint and Primary efficacy endpoint. Started Jan 2018; status: recruiting.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on MOH_2018-03-06_002206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-06_002206.